**Session: Session 1** – Tuesday, February 20, 2024

**Didactic Presenters:** [**Andrew M. Wolf, MD, MACP**](https://uvahealth.com/findadoctor/Andrew-Wolf-1235266610), Professor, Internal Medicine, University of Virginia, School of Medicine and [**Yaw A. Nyame, MD, MS, MBA**](https://www.fredhutch.org/en/provider-directory/yaw-a-nyame.html), Assistant Professor, Director of Urology, Fred Hutch Cancer Center at University of Washington School of Medicine

**Didactic Topic:** **The Science of Prostate Cancer Screening: Risks, Benefits, and Strategies to Reduce Overdiagnosis and Overtreatment**

**Resources**

**Guidelines for Prostate Cancer Screening from Professional Organizations**

*American Cancer Society*

[**Recommendations for Prostate Cancer Early Detection**](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html)

*American Urological Association*

[**Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)**](https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines)

*National Comprehensive Cancer Network*

[**NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023**](https://jnccn.org/view/journals/jnccn/21/3/article-p236.xml)

**Didactic Bibliography**

Andriole, Gerald L., et al. “Mortality results from a randomized prostate-cancer screening trial.” *New England Journal of Medicine*, vol. 360, no. 13, 26 Mar. 2009, pp. 1310–1319, <https://doi.org/10.1056/nejmoa0810696>.

Chang, Edward K., et al. “Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?” *Asian Journal of Urology*, vol. 8, no. 4, Oct. 2021, pp. 343–353, <https://doi.org/10.1016/j.ajur.2021.06.003>.

Cooperberg, Matthew R., et al. “Time Trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US.” *JAMA Network Open*, vol. 6, no. 3, 2 Mar. 2023, <https://doi.org/10.1001/jamanetworkopen.2023.1439>.

Grossman, David C., et al. “Screening for prostate cancer.” *JAMA*, vol. 319, no. 18, 8 May 2018, p. 1901, <https://doi.org/10.1001/jama.2018.3710>.

Hamdy, Freddie C., et al. “Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer.” *New England Journal of Medicine*, vol. 388, no. 17, 27 Apr. 2023, pp. 1547–1558, <https://doi.org/10.1056/nejmoa2214122>.

Hugosson, Jonas, et al. “Prostate cancer screening with PSA and MRI followed by targeted biopsy only.” *New England Journal of Medicine*, vol. 387, no. 23, 8 Dec. 2022, pp. 2126–2137, <https://doi.org/10.1056/nejmoa2209454>.

Klotz, Laurence, et al. “Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.” *Journal of Clinical Oncology*, vol. 33, no. 3, 20 Jan. 2015, pp. 272–277, <https://doi.org/10.1200/jco.2014.55.1192>.

Martin, Richard M., et al. “Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality.” *JAMA*, vol. 319, no. 9, 6 Mar. 2018, p. 883, <https://doi.org/10.1001/jama.2018.0154>.

Moyer, Virginia A. “Screening for cervical cancer: U.S. Preventive Services Task Force Recommendation Statement.” *Annals of Internal Medicine*, vol. 156, no. 12, 19 June 2012, p. 880, <https://doi.org/10.7326/0003-4819-156-12-201206190-00424>.

Mühlberger, Nikolai, et al. “Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and Policy Model.” *BMC Public Health*, vol. 17, no. 1, 26 June 2017, <https://doi.org/10.1186/s12889-017-4439-9>.

Nyame, Yaw A, et al. “The impact of intensifying prostate cancer screening in Black Men: A Model-based analysis.” *JNCI: Journal of the National Cancer Institute*, vol. 113, no. 10, 8 May 2021, pp. 1336–1342, <https://doi.org/10.1093/jnci/djab072>.

Preston, Mark A., et al. “Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer.” *Journal of Clinical Oncology*, vol. 34, no. 23, 10 Aug. 2016, pp. 2705–2711, <https://doi.org/10.1200/jco.2016.66.7527>.

Resnick, Matthew J., et al. “Long-term functional outcomes after treatment for localized prostate cancer.” *New England Journal of Medicine*, vol. 368, no. 5, 31 Jan. 2013, pp. 436–445, <https://doi.org/10.1056/nejmoa1209978>.

Schröder, Fritz H, et al. “Screening and prostate cancer mortality: Results of the European randomised study of screening for Prostate cancer (ERSPC) at 13 years of follow-up.” *The Lancet*, vol. 384, no. 9959, Dec. 2014, pp. 2027–2035, [https://doi.org/10.1016/s0140-6736(14)60525-0](https://doi.org/10.1016/s0140-6736%2814%2960525-0).

“Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement.” *Annals of Internal Medicine*, vol. 149, no. 9, 4 Nov. 2008, p. 627, <https://doi.org/10.7326/0003-4819-149-9-200811040-00243>.

Shah, Anand, et al. “Implementation and impact of a risk-stratified prostate cancer screening algorithm as a clinical decision support tool in a primary care network.” Journal of General Internal Medicine, vol. 36, no. 1, 1 Sept. 2020, pp. 92–99, <https://doi.org/10.1007/s11606-020-06124-2>.

Shoag, Jonathan E., et al. “Reconsidering the trade-offs of prostate cancer screening.” *New England Journal of Medicine*, vol. 382, no. 25, 18 June 2020, pp. 2465–2468, <https://doi.org/10.1056/nejmsb2000250>.

Siegel, Rebecca L., et al. “Cancer statistics, 2024.” *CA: A Cancer Journal for Clinicians*, vol. 74, no. 1, Jan. 2024, pp. 12–49, <https://doi.org/10.3322/caac.21820>.

Tosoian, Jeffrey J., et al. “Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer.” *Journal of Clinical Oncology*, vol. 33, no. 30, 20 Oct. 2015, pp. 3379–3385, <https://doi.org/10.1200/jco.2015.62.5764>.

Vickers, A. J., et al. “Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study.” *BMJ*, vol. 346, no. apr15 5, 16 Apr. 2013, <https://doi.org/10.1136/bmj.f2023>.

Wei, John T., et al. “Early detection of prostate cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.” *Journal of Urology*, vol. 210, no. 1, July 2023, pp. 46–53, <https://doi.org/10.1097/ju.0000000000003491>.

“Who Is at Risk for Prostate Cancer?” *Centers for Disease Control and Prevention*, Centers for Disease Control and Prevention, 17 July 2023, [www.cdc.gov/cancer/prostate/basic\_info/risk\_factors.htm](http://www.cdc.gov/cancer/prostate/basic_info/risk_factors.htm).

Wolf, A. M., et al. “American Cancer Society guideline for the early detection of prostate cancer: Update 2010.” *CA: A Cancer Journal for Clinicians*, vol. 60, no. 2, 1 Mar. 2010, pp. 70–98, <https://doi.org/10.3322/caac.20066>.